NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Clinical trials for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for bladder cancer patients: gene therapy delivered directly into the bladder
Disease control Recruiting nowThis study tests a new drug called EG-70 for a type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder through a tube. The goal is to see if it can shrink or eliminate tumors in people whose cancer didn't respond to standard BCG ther…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE1, PHASE2 • Sponsor: enGene, Inc. • Aim: Disease control
Last updated May 17, 2026 07:10 UTC
-
New gene therapy combo offers hope for tough bladder cancer
Disease control Recruiting nowThis phase 3 trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemotherapy or immunotherapy. It is for people with a type of bladder cancer (non-muscle invasive) that has not responded to standard BCG therapy. The s…
Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU
Phase: PHASE3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:49 UTC